Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, 466-8650, Japan.
Sci Rep. 2022 Jan 10;12(1):419. doi: 10.1038/s41598-021-04335-z.
We aimed to assess some of the potential genetic pathways for cancer development from non-malignant intraductal papillary mucinous neoplasm (IPMN) by evaluating genetic mutations and methylation. In total, 46 dissected regions in 33 IPMN cases were analyzed and compared between malignant-potential and benign cases, or between malignant-potential and benign tissue dissected regions including low-grade IPMN dissected regions accompanied by malignant-potential regions. Several gene mutations, gene methylations, and proteins were assessed by pyrosequencing and immunohistochemical analysis. RASSF1A methylation was more frequent in malignant-potential dissected regions (p = 0.0329). LINE-1 methylation was inversely correlated with GNAS mutation (r = - 0.3739, p = 0.0105). In cases with malignant-potential dissected regions, GNAS mutation was associated with less frequent perivascular invasion (p = 0.0128), perineural invasion (p = 0.0377), and lymph node metastasis (p = 0.0377) but significantly longer overall survival, compared to malignant-potential cases without GNAS mutation (p = 0.0419). The presence of concordant KRAS and GNAS mutations in the malignant-potential and benign dissected regions were more frequent among branch-duct IPMN cases than among the other types (p = 0.0319). Methylation of RASSF1A, CDKN2A, and LINE-1 and GNAS mutation may be relevant to cancer development, IPMN subtypes, and cancer prognosis.
我们旨在通过评估基因突变和甲基化来评估非恶性管内乳头状黏液性肿瘤 (IPMN) 中癌症发展的一些潜在遗传途径。总共分析了 33 例 IPMN 病例中的 46 个解剖区域,并将其与恶性潜能和良性病例进行比较,或与包括低级别 IPMN 解剖区域在内的恶性潜能和良性组织解剖区域进行比较,这些区域伴有恶性潜能区域。通过焦磷酸测序和免疫组织化学分析评估了几个基因突变、基因甲基化和蛋白质。RASSF1A 甲基化在恶性潜能解剖区域中更为频繁 (p=0.0329)。LINE-1 甲基化与 GNAS 突变呈负相关 (r=-0.3739, p=0.0105)。在具有恶性潜能解剖区域的病例中,与无 GNAS 突变的恶性潜能病例相比,GNAS 突变与较少的血管周围侵犯 (p=0.0128)、神经周围侵犯 (p=0.0377) 和淋巴结转移 (p=0.0377) 相关,但总生存期显著延长 (p=0.0419)。在恶性潜能和良性解剖区域中存在一致的 KRAS 和 GNAS 突变的病例在分支导管 IPMN 病例中比其他类型更为常见 (p=0.0319)。RASSF1A、CDKN2A 和 LINE-1 的甲基化以及 GNAS 突变可能与癌症发展、IPMN 亚型和癌症预后有关。